珍宝岛(603567) - 2021 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2021 was ¥1,072,990,343.47, representing a year-on-year increase of 160.39%[7] - The net profit attributable to shareholders was a loss of ¥33,852,631.99, a decrease of 160.06% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of ¥44,698,960.45, with a significant increase of 349.03% year-to-date[7] - The basic and diluted earnings per share were both -¥0.0398, reflecting a decrease of 159.94% year-on-year[9] - Revenue for the period from the beginning of the year to the end of the reporting period was 52.27 million, mainly driven by the growth in traditional Chinese medicine business[14] - Operating costs for the same period reached 137.34 million, also attributed to the increase in traditional Chinese medicine business[14] - The company reported a net profit of CNY 3.24 billion for the first nine months of 2021, up from CNY 2.99 billion in the same period last year[30] - Total operating revenue for the first three quarters of 2021 reached RMB 2,704,740,106.96, a 52.5% increase from RMB 1,780,776,566.44 in the same period of 2020[34] - Operating profit for the third quarter of 2021 was RMB 296,631,230.15, compared to RMB 315,434,418.04 in the third quarter of 2020, reflecting a decrease of 5.5%[36] - Net profit attributable to shareholders of the parent company for the third quarter of 2021 was RMB 242,419,593.26, slightly up from RMB 240,821,172.25 in the same quarter of 2020, indicating a growth of 0.7%[36] Assets and Liabilities - The total assets at the end of the reporting period were ¥10,234,117,571.86, showing a slight decrease of 0.00% compared to the end of the previous year[9] - The equity attributable to shareholders increased to ¥5,737,028,476.17, marking a year-on-year growth of 4.42%[9] - The company reported a significant decrease of 79.83% in cash and cash equivalents at the end of the reporting period, primarily due to payments for herbal medicine and R&D expenses[12] - Inventory increased by 32.49% at the end of the reporting period, mainly due to an increase in herbal materials[12] - Long-term equity investments at the end of the reporting period amounted to 40.89 million, primarily due to increased investment payments to associated companies[14] - The company's total assets amounted to CNY 10.23 billion, with current assets totaling CNY 5.31 billion[24] - Total liabilities were reported at CNY 4.49 billion, a decrease from CNY 4.73 billion year-over-year[30] - The company’s long-term borrowings stood at CNY 2.12 billion, slightly down from CNY 2.13 billion year-over-year[30] - The company’s total non-current assets amounted to CNY 4.92 billion, an increase from CNY 4.23 billion in the previous year[30] - The company’s total liabilities and equity amounted to CNY 10.23 billion, consistent with the total assets reported[33] Cash Flow - The net cash flow from operating activities for the year-to-date was -¥500,324,395.95, indicating a negative cash flow situation[9] - Net cash flow from operating activities for the period was -337.11 million, mainly due to reduced sales collections during the pandemic and increased payments for raw material purchases[14] - Cash flow from investing activities for the period was 46.11 million, primarily due to increased proceeds from the sale of wholly-owned subsidiary equity[14] - Cash flow from financing activities for the period was -157.28 million, mainly due to adjustments in the borrowing structure[14] - Cash received from borrowings was $520,000,000.00, down from $1,940,000,000.00[42] - Cash paid for debt repayment was $569,000,000.00, compared to $1,372,886,295.00 previously[42] - Cash paid for dividends and interest was $108,895,354.71, a decrease from $425,780,138.16[42] - The net increase in cash and cash equivalents was -$1,240,263,192.14, worsening from -$1,022,404,269.05[42] - The ending balance of cash and cash equivalents was $261,597,089.10, significantly lower than $1,483,056,215.26 at the beginning of the period[42] Shareholder Information - The total number of common shareholders at the end of the reporting period was 16,476[14] - The top ten shareholders held a total of 579.89 million shares, representing 68.29% of the total shares[17] Non-Recurring Gains and Expenses - Non-recurring gains included government subsidies amounting to ¥14,088,525.93 for the year-to-date[10] - The company reported a decrease in tax and additional charges to RMB 49,913,584.26 in 2021 from RMB 102,867,926.50 in 2020, a reduction of 51.5%[34] - Research and development expenses for the first three quarters of 2021 were RMB 37,187,830.90, down 22.7% from RMB 48,094,535.80 in the same period of 2020[34] - The company recorded an investment income of RMB 151,656,264.63 for the first three quarters of 2021, down from RMB 240,122,890.14 in the same period of 2020, a decline of 37.0%[34] - The company reported a significant increase in fixed asset disposal income, amounting to 131.96 million, indicating improved asset management[14] Equity Transactions - The company transferred 100% equity of its wholly-owned subsidiaries to Heilongjiang Zhenbao Island Group for a transfer payment of CNY 423 million, representing 53.36% of the total transfer amount[22] Leasing Standards - The company has not applied the new leasing standards since 2021[43]